反侧缩缩剂量预测头癌辐射后的吞功能
1Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana.
概括
辐射剂量到对侧喉收缩肌肉预测了头癌幸存者的吞问题. 较低剂量可以降低消化不良的风险,改善生活质量.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 吞障碍 吞障碍 吞障碍
背景情况:
- 长期的消化不良是头癌幸存者治疗放射治疗的重要生活质量问题.
- 识别晚期吞功能障碍的预测因素对于改善患者的治疗结果至关重要.
研究的目的:
- 评价相对侧的喉收缩肌肉作为一个有风险的器官.
- 为了确定这个结构的辐射剂量是否预测了头癌患者晚期吞功能.
主要方法:
- 头癌患者接受放射治疗和并发全身治疗的回顾性研究.
- 辐射后1年评估的消化不良,定义为胃口管依赖或异常修饰的吞.
- 对对侧收缩肌肉 (V60) 和未涉及喉的辐射剂量的分析.平均剂量.
主要成果:
- 37%的患者经历了1年的消化不良.
- 逆侧缩剂V60<40%与显著较低的消化障碍率相关 (6%与57%相比).
- 平均喉剂量<45 Gy和空气腔编辑也与减少食障碍相关.
结论:
- 这是第一个将 contralateral constrictor 辐射剂量与晚期吞功能联系起来的研究.
- 反侧约束剂量可能会受到治疗技术的影响,例如空气腔编辑.
- 需要进行前性验证,以在不同的临床环境中证实这些发现.
相关概念视频
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
237
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
237
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
190
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
190